A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
1997

Study of Carboplatin and Paclitaxel for Ovarian Cancer

Sample size: 12 publication Evidence: low

Author Information

Author(s): N Siddiqui, AV Boddy, HD Thomas, NP Bailey, L Robson, MJ Lind, AH Calvert

Primary Institution: Northern Centre for Cancer Treatment, Newcastle General Hospital; Department of Oncology, University of Newcastle upon Tyne

Hypothesis

The study aims to determine the maximum tolerated dose of a combination of carboplatin and paclitaxel and evaluate any possible pharmacokinetic interaction.

Conclusion

The combination of carboplatin and paclitaxel may be administered as first-line treatment for advanced ovarian cancer, with manageable toxicity.

Supporting Evidence

  • Grade 3 or 4 neutropenia was seen in 70% of the courses.
  • Grade 3 or 4 thrombocytopenia occurred in 24% of the courses.
  • The AUC of carboplatin was 7.0±1.4 mg ml-' min, indicating no pharmacokinetic interaction.
  • Ten patients completed the treatment of six cycles each.

Takeaway

Doctors wanted to find out how much of two cancer drugs, carboplatin and paclitaxel, can be given together safely to help women with ovarian cancer.

Methodology

This phase I study involved treating twelve chemonaive patients with escalating doses of paclitaxel followed by carboplatin, with pharmacokinetic studies performed on nine patients.

Limitations

The results need to be confirmed in future investigations due to the small sample size.

Participant Demographics

Patients were aged between 18-75 years, with histologically proven epithelial ovarian cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication